Evaluating Therapeutic Interventions: Some Issues and Experiences
In frequently occurring life-threatening diseases such as cancer, AIDS and cardiovascular disease, there is a need of significant public health importance for rapid yet reliable evaluation of promising new therapeutic interventions that might provide greater efficacy and reduced toxicity. Leadership from statistical scientists is essential to effectively address many of the challenges resulting from this need. By discussing recent experiences, primarily in the area of oncology and AIDS clinical trials, we will illustrate several of these challenges. We also will review some designs and methods that have been implemented in these settings. Particular attention will be given to experiences from involvement with FDA Advisory Committees and with Data Monitoring Committees for clinical trials sponsored by industry or by the National Institutes of Health. Among issues to be discussed will be the role of independent monitoring committees and group sequential guidelines in randomized clinical trials, the evaluation of equivalence trials and the use of surrogate and auxiliary endpoints.
Group sequential designs . interim analyses . data monitoring committees . administrative analyses . repeated confidence intervals . equivalence trials . active control designs . auxiliary endpoints . surrogate markers . estimated likelihood . augmented score . estimating equations.
원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.
NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.
- 이 논문과 함께 출판된 논문 + 더보기